Bangalore in India, is an extremely cosmopolitan city located in the southern part of India. It has a good number of expat crowds working for the Information Technology Sector. It has great weather throughout the year and fantastic connectivity to the world through a world class International Airport. We will guide you all along and help you overcome the language barrier, work culture, general anxiety of being in a foreign country, procedural requirements and staying connected with your loved ones back home either through calls or the Internet. All information that we provide can be corroborated online before you make your booking. We will make the entire process as smooth and transparent as possible.
Cost Effective
You can wrap up your entire treatment at fraction of the cost and will not have to wait for your medication.
You can cure the disease in a timely manner and lead a healthy and stress free life.
You get the very same medication licensed from the company that found the cure. Can it get better?
The Best of Doctors
The Medical System is quite advanced and we have people from neighboring countries flying in for treatment related to Heart,Dental,Eyes and other complicated surgeries. We perform open heart surgeries at 1/10 the cost of what it is in most developed countries.
Gilead
Gilead Announces Generic Licensing Agreements to Increase Access to Hepatitis C Treatments in Developing Countries. September 15, 2014 6:31 AMET — Indian companies granted license to produce generic sofosbuvir and investigational single tablet regimen of ledipasvir/sofosbuvir for treatment of chronic hepatitis C —
NEW DELHI–(BUSINESS WIRE)–Sep. 15, 2014– Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company has signed non-exclusive licensing agreements with seven India-based generic pharmaceutical manufacturers to expand access to its chronic hepatitis C medicines in developing countries. The agreements allow the companies – Cadila Healthcare Ltd., Cipla Ltd., Hetero Labs Ltd., Mylan Laboratories Ltd., Ranbaxy Laboratories Ltd., Sequent Scientific Ltd. and Strides Arcolab Ltd. – to manufacture sofosbuvir and the investigational single tablet regimen of ledipasvir/sofosbuvir for distribution in 91 developing countries.
The countries within the agreement account for more than 100 million people living with hepatitis C, representing 54% of the total global infected population.
Under the licensing agreements, the Indian companies receive a complete technology transfer of the Gilead manufacturing process to enable them to scale up production as quickly as possible. The licensees also set their own prices for the generic product they produce, paying a royalty on sales to Gilead to support product registrations, medical education and training, safety monitoring and other essential business activities. The licenses also permit the manufacture of sofosbuvir or ledipasvir in combination with other chronic hepatitis C medicines.
Sofosbuvir was approved under the trade name Sovaldi by the U.S. Food and Drug Administration (FDA) in December 2013 and by the European Commission in January 2014.
Click on click below which takes you to the Gilead website confirming the Licensing Agreement.